Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | GRM8 | O00222 | 1/20 | 0.72 |
| ▸ | GRM6 | O15303 | 1/20 | 0.72 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.72 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.72 |
| ▸ | GRM5 | P41594 | 1/20 | 0.72 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.72 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.72 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.72 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.72 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.72 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.72 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.72 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.72 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.72 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL8000337 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL27400214 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL7258645 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1079951 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL1079952 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL8000334 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL2415481 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL205003 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL21796040 | 1.00 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL6034319 | 0.98 | GSR (0.77) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005040338-A2 | CONSTRAINED ALKALOID IMMUNOGENS AND ANTIBODIES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-05-06 | — | — | WO | claimed |
| US-20240156961-A1 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | BIONTECH US INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024077256-A9 | METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OF PEPTIDE-MHC TARGETING BINDING PROTEINS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11965892-B2 | HLA-based methods and compositions and uses thereof | BIONTECH US INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024081791-A2 | COMPOSITIONS AND METHODS FOR MAINTAINING A CCL3/CCL4 AND CCR5 INTERACTION PROGRAM EXPRESSED DURING TUMOR PROGRESSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240115678-A1 | PERSONALIZED MULTIDISCIPLINARY CANCER THERAPY | VELTMEYER JAMES (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024077256-A1 | METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OFPEPTIDE-MHC TARGETING BINDING PROTEINS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240108690-A1 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | ELI LILLY AND COMPANY | 2024-04-04 | — | — | US | disclosed |
| US-20240100139-A1 | NEOANTIGENS AND USES THEREOF | BIONTECH US INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240100160-A1 | ENHANCEMENT OF T CELL HOMING TO TUMORS THROUGH AUGMENTATION OF CHEMOKINE RESPONSIVENESS AND ACTIVATION DEPENDENT CHEMOKINE SECRETION | Regen BioPharma, Inc. (US) | 2024-03-28 | — | — | US | disclosed |
| US-4599231-A | MIXTURES OF POLYPOEPTIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-07-08 | — | — | US | disclosed |
| US-4599230-A | POLYPEPTIDE ANTIGENS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-07-08 | — | — | US | disclosed |
| WO-1985004653-A1 | ANTIBODIES TO HUMAN INTERLEUKIN-2 INDUCED BY SYNTHETIC POLYPEPTIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-10-24 | — | — | WO | disclosed |
| EP-0157643-A2 | Antibodies to human interleukin-2 induced by synthetic polypeptides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-10-09 | — | — | EP | disclosed |
| WO-1985004103-A1 | SYNTHETIC HEPATITIS B VIRUS VACCINE INCLUDING BOTH T CELL ANC B CELL DETERMINANTS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-26 | — | — | WO | disclosed |
| EP-0155147-A2 | The antigenic determinants of HBxAg | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0155146-A2 | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-18 | — | — | EP | disclosed |
| WO-1985003950-A1 | A SV40 EXPRESSION VECTOR CONTAINING HBXAG AS AN EXPRESSION MARKER | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-12 | — | — | WO | disclosed |
| EP-0119702-A2 | Synthetic polypeptides from viral oncogenes | Sen, Arup (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984003087-A1 | SYNTHETIC POLYPEPTIDES FROM VIRAL ONCOGENES | SEN ARUP | 1984-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108690-A1 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | PDCD10, CD274, PDCD1 | GSR 4191/4885CYP1A2 4474/4885GRM8 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.